Simple blood test could help monitor aggressive brain tumors
NCT ID NCT05157594
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at whether a blood test measuring a protein called hPG80 (progastrin) can help track high-grade brain tumors like glioblastoma. Researchers took blood samples from 30 patients before, during, and after radiation and chemotherapy. The goal was to see if hPG80 levels change with tumor progression or treatment, potentially offering a less invasive way to monitor the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple blood test to monitor brain tumor progression and response to treatment.
- What could go wrong
- This is a very small pilot study (30 people) with no control group, so results may not apply broadly. The test is experimental and not yet proven to be reliable.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAPLASTIC OLIGODENDROGLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Jean PERRIN
Clermont-Ferrand, 63011, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a seizure drug outsmart a deadly brain tumor?
- A simple lotion duo may shield skin from Tumor-Treating fields
- Can a One-Two punch slow recurrent brain cancer?